At a glance
ClinicalIndex Comparison RecordN/ACompleted· 74 enrolled
Drug / intervention
Certolizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Lipids, Inflammation, and Cardiovascular Risk in Rheumatoid Arthritis
In Brief
An observational study evaluating Certolizumab for Rheumatoid Arthritis and Cardiovascular Disease. Completed, enrolled 74 participants across 1 site.
Detailed Summary
The objective of this study was to examine the relationship between inflammation, lipids, and cardiovascular risk in rheumatoid arthritis. The central hypothesis is that reducing inflammation will reduce cardiovascular risk as measured by coronary flow reserve. Additionally, we hypothesized that lipid levels may have a weaker correlation with CV risk compared to the general population.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis, Cardiovascular Disease
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 2016
Enrollment StartOct 2016
Primary CompletionDec 2020
Study CompletionDec 2022
TodayJul 2026
First PostedMar 22, 2016
Enrollment StartOct 17, 2016
Primary CompletionDec 14, 2020
Study CompletionDec 21, 2022
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 10.3 years ago
Interventions
Certolizumabdrug